<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
  <title>Eurotrack: EQT</title>
  <subtitle>All entries on EQT across all areas, newest first.</subtitle>
  <link href="https://eurotrack.ai/en/companies/eqt/"/>
  <link rel="self" href="https://eurotrack.ai/en/companies/eqt/feed.xml"/>
  <id>tag:eurotrack.ai,2026:en:en/companies/eqt</id>
  <updated>2026-10-21T06:00:00Z</updated>
  <author><name>Eurotrack</name></author>
  <entry>
    <title>🤝 EQT to acquire Qiagen for €46.50 per share in cash (Sweden / Netherlands)</title>
    <link href="https://eurotrack.ai/en/developments/4bd2ef58-eqt-to-acquire-qiagen-for-46-50-per-share-in-cash/"/>
    <id>tag:eurotrack.ai,2026:4bd2ef58:en</id>
    <updated>2026-10-21T06:00:00Z</updated>
    <summary>On 21 October 2026 Qiagen signed a business combination agreement with EQT's bidder Crown NL Bidco: a voluntary public cash offer of €46.50 per share values the diagnostics group at about €10.8bn (enterprise value). According to the company, closing is planned for mid-2027 and depends on a minimum acceptance level and regulatory clearances, after which the stock market listings are to end. Qiagen also suspends its 2026 outlook (Qiagen, ad hoc notice, 21 Oct 2026; second source: RTTNews, 22 Oct 2026). — Sources: https://www.finanznachrichten.de/nachrichten-2026-10/69900484-eqs-adhoc-qiagen-n-v-abschluss-einer-vereinbarung-ueber-einen-unternehmenszusammenschluss-mit-eqt-private-equity-vorlaeufige-ergebnisse-fuer-das-3-q-022.htm · https://www.rttnews.com/3701422/qiagen-agrees-to-eqt-takeover-offer-for-all-outstanding-shares-at-46-50-share.aspx</summary>
  </entry>
  <entry>
    <title>🤝 EQT to acquire TachoSil biosurgery business from Corza Medical (Austria)</title>
    <link href="https://eurotrack.ai/en/developments/c3f308b5-eqt-to-acquire-tachosil-biosurgery-business-from-corza/"/>
    <id>tag:eurotrack.ai,2026:c3f308b5:en</id>
    <updated>2026-07-07T06:00:00Z</updated>
    <summary>EQT is buying Corza Medical's business built around the TachoSil haemostatic patch, with manufacturing in Linz and about 400 staff worldwide; no price or revenue was given and closing is expected in Q4 2026 (EQT, 7 July 2026). Update (23 September 2026): the European Commission cleared the deal as case M.12554 (European Commission, Daily News, 23 September 2026). — Sources: https://eqtgroup.com/news/eqt-to-acquire-the-tachosil-biosurgery-business-from-corza-medical-2026-07-07 · https://ec.europa.eu/commission/presscorner/detail/en/mex_26_1951</summary>
  </entry>
  <entry>
    <title>🤝 EQT to acquire satellite launch services provider Exolaunch (Sweden / Germany)</title>
    <link href="https://eurotrack.ai/en/developments/f7901896-eqt-to-acquire-satellite-launch-services-provider-exolaunch/"/>
    <id>tag:eurotrack.ai,2026:f7901896:en</id>
    <updated>2026-06-18T06:00:00Z</updated>
    <summary>EQT is acquiring Germany-based satellite deployment and launch mission management firm Exolaunch through its EQT X fund; no price or figures were given and closing was expected in Q4 2026 (EQT, 18 June 2026). Update (14 September 2026): the European Commission cleared the deal as case M.12534 (European Commission, Daily News, 14 September 2026). — Sources: https://www.inderes.se/en/releases/eqt-to-acquire-exolaunch-a-germany-based-satellite-deployment-technology-and-launch-mission-management-firm-powering-global-access-to-space · https://ec.europa.eu/commission/presscorner/detail/en/mex_26_1864</summary>
  </entry>
</feed>
